NCT05998941 is a Phase 2 clinical trial of TQB2868 injection in Cervical Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

Who is sponsoring NCT05998941?

NCT05998941 is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

What drugs are being tested in NCT05998941?

Interventions in NCT05998941: TQB2868 injection, Paclitaxel injection, Cisplatin injection, Carboplatin injection, Bevacizumab injection.

What condition does NCT05998941 study?

NCT05998941 studies Cervical Cancer.

Is NCT05998941 still recruiting?

NCT05998941 is currently withdrawn. Last updated 20 November 2023.

Last reviewed 2023-11-20 · How we verify

NCT05998941

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer: a Single-arm, Open-label Phase Ⅱ Study

Withdrawn Phase 2 Last updated 20 November 2023

What this trial tests

Phase 2 trial testing TQB2868 injection in Cervical Cancer. Withdrawn.

Timeline

1 August 2023

Primary endpoint
1 February 2025

1 June 2025

Quick facts

Lead sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 August 2023
Primary completion	1 February 2025
Estimated completion	1 June 2025
Sites	2 locations across China

Drugs / interventions tested

TQB2868 injection — full drug profile →
Paclitaxel injection — full drug profile →
Cisplatin injection — full drug profile →
Carboplatin injection — full drug profile →
Bevacizumab injection — full drug profile →

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Investigator-assessed objective response rate (ORR)
Time frame: Baseline to CR or PR ,about 12 months
The proportion of subjects who achieve a prespecified reduction in tumor volume and maintain the minimum time requirement, including complete response (CR) and partial response (PR).

Sponsor's own description

This study used a single-arm, open phase II multicenter trial design. All eligible subjects received TQB2868 plus platinum-based chemotherapy with or without bevacizumab. A total of 39 subjects will be enrolled.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting transforming growth factor beta signaling in metastatic osteosarcoma.
Ge R, Huang GM. · · 2023 · cited 25× · PMID 38021074 · DOI 10.1016/j.jbo.2023.100513
Unraveling the Role of the Tumor Extracellular Matrix to Inform Nanoparticle Design for Nanomedicine.
Cassani M, Fernandes S, Pagliari S, Cavalieri F, et al · · 2025 · cited 24× · PMID 39629891 · DOI 10.1002/advs.202409898

Verify or expand the search:

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other Chia Tai Tianqing Pharmaceutical Group Co., Ltd. trials

Trials by the same sponsor.

NCT06990776 — A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects · Phase 2 · withdrawn
NCT06851442 — Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced o · Phase 1, PHASE2 · terminated
NCT06711991 — A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease · Phase 1 · completed
NCT06672276 — To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency · Phase 1 · completed
NCT06644417 — Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Tre · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05998941 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Last refreshed: 20 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05998941.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing